Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases

Discussing the FRBM special issue 'Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases' published in the September 2022 issue of the journal.

Speaker: Dr. Elias Arner, Karolinska Institutet, Sweden
Moderator: Prof. Henry J Forman, University of Southern California, USA

0:44 Introduction of Dr. Elias Arner
1:30 How and why Dr. Arner moved into selenium and thioredoxin research
6:48 Activities of TrxR and its multiple domains
10:18 How substitution of sulfurs in selenium results in a less or completely inactive thioredoxin reductase
16:25 Reduction of small molecules - is that just a lab curiosity or physiologically significant?
18:34 The good and the bad of modulating thioredoxin reductase activity
26:30 How there's a critical role for thioredoxin reductase in parasites
31:20 When you use thioredoxin reductase inhibitors in diseases, how do you go about it in a way that does not cause havoc?
34:35 Speculation on why there are 25 seleno proteins identified in animals but the activity of many of them remains a mystery
38:02 Advice for young investigators 
41:06 Dr. Arner's work outside of science as an artist and writer